Physician profile
Brian Grieb
NPI 1609220714
$4,163.68
in general payments reported to CMS, 2019-2025
9 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,823 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,924 · Consulting Fee: $1,875 · Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,924.03 |
| Consulting Fee | $1,875.00 |
| Food and Beverage | $364.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $3,822.93 | 2024 | |
| Kite Pharma, INC. | $146.83 | 2025 | Yescarta |
| Syndax Pharmaceuticals, INC. | $49.14 | 2025 | |
| Merck Sharp & Dohme LLC | $30.92 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Genzyme Corporation | $27.11 | 2025 | |
| Beone Medicines USA, INC. | $24.37 | 2025 | Tevimbra |
| Genentech USA, INC. | $22.13 | 2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $21.12 | 2025 | Iclusig |
| Karyopharm Therapeutics INC. | $19.13 | 2025 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Grieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.